1 |
|
INFO/audio |
0:39:41 |
Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more |
2 |
|
INFO/audio |
0:32:45 |
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s |
3 |
|
INFO/audio |
0:15:06 |
What can we learn from 2024’s biotech IPOs? |
4 |
|
INFO/audio |
0:12:30 |
Meet 2024’s fiercest women in life sciences |
5 |
|
INFO/audio |
0:15:29 |
Misconduct and the future of neurodegenerative disease research |
6 |
|
INFO/audio |
0:11:51 |
Dig into this year’s Fierce Biotech Graveyard, layoff numbers |
7 |
|
INFO/audio |
0:16:34 |
Drug pricing and the 2024 presidential election |
8 |
|
INFO/audio |
0:18:15 |
Discover Turbine’s way to build avatars true to patient biology [Sponsored] |
9 |
|
INFO/audio |
0:20:13 |
The pulse of the medtech industry |
10 |
|
INFO/audio |
0:32:49 |
Where are they now? Catching up with past Fierce 15 honorees |
11 |
|
INFO/audio |
0:23:55 |
Revolutionizing gene therapy logistics with Cryoport's Elite solution [Sponsored] |
12 |
|
INFO/audio |
0:40:29 |
A revival in neuro therapeutics |
13 |
|
INFO/audio |
0:20:02 |
Breaking down BIOSECURE—Industry implications and what comes next |
14 |
|
INFO/audio |
0:23:17 |
ESMO, WCLC lung cancer data spark hope—and debate |
15 |
|
INFO/audio |
0:08:23 |
Recapping Digital Pharma East 2024 |
16 |
|
INFO/audio |
0:07:24 |
A closer look at the Fierce 50 |
17 |
|
INFO/audio |
0:17:10 |
A look at flu vaccine manufacturing and supply in the post-pandemic era |
18 |
|
INFO/audio |
0:20:46 |
Driving flu vaccine uptake in the post-pandemic era |
19 |
|
INFO/audio |
0:13:42 |
The Crucial Role of HEK293 DNA Quantification in Biotherapeutics [Sponsored by Bio-Rad Laboratories] |
20 |
|
INFO/audio |
0:25:15 |
What Chevron’s overturn means for biopharma |
21 |
|
INFO/audio |
0:24:41 |
The TROP2 race for supremacy |
22 |
|
INFO/audio |
0:11:17 |
A closer look at Fierce Biotech's Fierce 15 |
23 |
|
INFO/audio |
0:26:38 |
What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development |
24 |
|
INFO/audio |
0:10:02 |
Fierce 15: Where are they now? |
25 |
|
INFO/audio |
0:17:18 |
Former FTC director weighs in on Novo's $16.5B deal with Catalent |
26 |
|
INFO/audio |
0:13:45 |
Find out what to expect from the PDA/FDA Joint Regulatory Conference (Sponsored by Parenteral Drug Association) |
27 |
|
INFO/audio |
0:10:47 |
A look at Big Pharma’s top-paid CEOs |
28 |
|
INFO/audio |
0:15:02 |
The best biopharma M&A deals |
29 |
|
INFO/audio |
0:17:54 |
A closer look at 'friend-shoring' and the drug shortage challenge |
30 |
|
INFO/audio |
0:13:35 |
Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth |
31 |
|
INFO/audio |
0:09:35 |
A look at the top 10 pharma drug ad spenders |
32 |
|
INFO/audio |
0:06:31 |
A cell therapy reckoning |
33 |
|
INFO/audio |
0:39:37 |
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III) |
34 |
|
INFO/audio |
0:17:00 |
[Sponsored] Opportunities & Challenges of Digital Pathology Adoption in CDx Development |
35 |
|
INFO/audio |
0:15:11 |
[Sponsored] Unlocking health equity: The promise of digital health technologies |
36 |
|
INFO/audio |
0:31:23 |
Advancements in cell & gene therapy manufacturing (Part II) |
37 |
|
INFO/audio |
0:29:15 |
Fulfilling the promise of cell & gene therapies through manufacturing (Part I) |
38 |
|
INFO/audio |
0:18:07 |
A closer look at 2023's top biopharma deals and what lies ahead |
39 |
|
INFO/audio |
0:10:28 |
A look at pharma revenue rankings |
40 |
|
INFO/audio |
0:14:30 |
Winning formulas for the best biotech and drug names |
41 |
|
INFO/audio |
0:11:34 |
[Sponsored] What does the future of specialist distribution look like? |
42 |
|
INFO/audio |
0:17:47 |
Deep dive: Biopharma layoffs in Q1 |
43 |
|
INFO/audio |
0:14:12 |
The unrecognized threat of PAD |
44 |
|
INFO/audio |
0:18:55 |
The top money raisers in biotech |
45 |
|
INFO/audio |
0:18:28 |
A closer look at European biotech investment in 2024 |
46 |
|
INFO/audio |
0:14:45 |
Inclusivity in psoriasis trials with Takeda |
47 |
|
INFO/audio |
0:16:20 |
Fierce Medtech's Fierce 15 |
48 |
|
INFO/audio |
0:16:02 |
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success |
49 |
|
INFO/audio |
0:33:57 |
CAR-T boxed warnings: What comes next? |
50 |
|
INFO/audio |
0:23:16 |
Breaking down Eli Lilly’s ESG formula |
51 |
|
INFO/audio |
0:25:44 |
Gene editing's next act |
52 |
|
INFO/audio |
0:11:06 |
The most anticipated drug launches of 2024 |